Kung A W, Choi P, Lam K S, Pun K K, Wang C, Yeung R T
Department of Medicine, University of Hong Kong.
Clin Radiol. 1990 Jul;42(1):52-4. doi: 10.1016/s0009-9260(05)81624-1.
Pretreatment clinical, biochemical, iodine-131 (131I) scan and tracer-kinetic parameters were studied in 827 Chinese patients with Graves' disease treated with radioactive iodine. One year after 131I therapy, 56.7% were euthyroid, 33.9% were still thyrotoxic and 9.4% were hypothyroid. Discriminant analysis of all pretreatment variables identified thyroid mass, presenting free thyroxine index and 4 h 131I uptake as the three variables most helpful in discriminating the early outcome group of 131I therapy. The findings suggest that patients with large goitres and severe disease may require higher doses of 131I for treatment of Graves' disease.
对827例接受放射性碘治疗的中国Graves病患者的治疗前临床、生化、碘-131（¹³¹I）扫描及示踪动力学参数进行了研究。¹³¹I治疗一年后，56.7%的患者甲状腺功能正常，33.9%的患者仍有甲状腺毒症，9.4%的患者出现甲状腺功能减退。对所有治疗前变量进行判别分析，确定甲状腺肿块、游离甲状腺素指数及4小时¹³¹I摄取率是最有助于判别¹³¹I治疗早期结果组的三个变量。研究结果表明，甲状腺肿大且病情严重的患者治疗Graves病可能需要更高剂量的¹³¹I。
